David Pook

Medical Oncologist specialising in urological cancers at Monash Cancer Centre. Clinical trial investigator and prostate cancer translational researcher.

[David Pook @docpook]

@DrMHofman @CraigUnderhill @ANZUPtrials @ciaraconduit @Prof_IanD @JeffreyCGoh1 @HowardGurney @doccharris @DrL_Krieger @Drdhadams @feliciaTSR @anthonyjoshua @LizHovey @DrCraigGedye @X @BJUIjournal I think the PBS should be funding de-escalation studies - we can all think of examples where it could save a lot of money

[ANZUP @ANZUPtrials]

Great to see @ANZUPtrials #UNICAB Study poster @ASCO #GU24 presented by @docpook. Well done to entire team for their ongoing hard work #kidneycancer #improvingoutcomes #BaCT @PeterMacCC @IpsenGroup @CancerAustralia @DrCraigGedye @Prof_IanD

[David Pook @docpook]

KN-564 shows significant improvement in overall survival in RCC with 12m of adjuvant pembro with HR 0.62. Meanwhile the Nivo arm of CM-914 is negative. Unsure if this is due to differences in drug activity or just duration of treatment. #GU24

[Yüksel Ürün @DrYukselUrun]

Delving into the ENZAMET trial: Radiographic progression in mHSPC may occur without PSA elevation, challenging conventional monitoring methods. The study underscores the complexity of disease progression. #ProstateCancer
@Prof_IanD @ChrisSweens1

@ASCO #GU24 @OncoAlert @urotoday @oncodaily @DrChoueiri @yekeduz_emre @sophia_kamran @BraunMDPhD @AmandaNizamMD @TiansterZhang @RCCadvocate @ShuchiGulati @RuchikaTalwarMD @DrKarineTawagi @neerajaiims @montypal @crisbergerot @DrRanaMcKay @Tilki_De @CParkMD @cdanicas @FabioSchutz78 @PGrivasMDPhD

[ANZUP @ANZUPtrials]

Great @ANZUPtrials poster @ASCO #GU24 Baseline disease characteristics of participants enrolled on #ENZARAD & #DASLHiCaP Congrats @niazi_Dr7 @ChrisSweens1 @DrPaulNguyen & Scott Williams @TrialsCentre @ThePCCTC @cancertrials_ie @CDNCancerTrials @MSKCancerCenter @AstellasUS @Bayer

[David Pook @docpook]

CONTACT-02 Study showed improvement in rPFS in CRPC patients with soft tissue disease from 4.2m to 6.3m with Cabo/Atezo vs ARSI switch. Lots of questions about the ethics of randomising a patient with liver mets to ARSI switch. I would not be comfortable doing this. #GU24

[David Pook @docpook]

BrCAAway study reports 39m rPFS with Abi+Olap in mCRPC with HRD, 8.4m for Abi and 14m for Olap. Possible synergy but less than 1/3 of monotherapy pts crossed over. 50% of pts screened for HRD were +ve which is far higher than we see in clinic. #GU24

[David Pook @docpook]

@EdmondMKwan @ConquerCancerFd @VanProstateCtr @ResearchWyatt @BCCancer @MurthaAj @PCF_Science Awesome Ed see you there!

[David Pook @docpook]

Very sad what we’re seeing around the World #endhate

[Toni Choueiri, MD @DrChoueiri]

JUST IN: some news in metastatic bladder cancer combinations via ⁦@Reuters⁩

https://t.co/z3NKmYaw4K https://t.co/z3NKmYaw4K

[Tom Powles @tompowles1]

Gem/cis & nivolumab achieves significant PFS & OS in 1st line UC . Maintenance avelumab = 25% ⬆️ in OS, but not all pts get there. Better disease control during the chemo phase and competitive OS HR will be attractive to patients. https://t.co/rnwSxiBKhl

[Laurence Albiges @AlbigesL]

Pleased to share @TheLancetOncol LENVA-PEMBRO across RCC variant histologies: papillary RCC, unclRCC and chromophobe RCC … interim @myESMO #ESMO22 and final @ChungHanLee3 @ASCO #ASCO23

full text: https://t.co/QioxQEiKho
Thanks to all who change
rareRCC pts Tx!

[Ben Tran @DrBenTran]

Liz Liow presenting KRAB data (Australian real world kidney cancer data) @ANZUPtrials #ANZUP23 at best of the best oral abstract session @WEHI_research @DrDanielHeng

[David Pook @docpook]

@DrCraigGedye explaining adaptive hormone therapy in prostate cancer on #EnzAdapt trial - tx is paused following a PSA response and then restarted on PD. Advantages are:
👉 patient gets a break from therapy 👉 may take longer for the cancer to develop resistance
#ANZUP23

[David Pook @docpook]

Mitch Lawrence explaining how high dose testosterone can be used to treat prostate cancer and how his team are investigating this in PDX models #ANZUP23

[Marc Diocera @MarcDiocera]

.@DrDarrenFeldman on Challenges & Pitfalls in #GCT Management | #ANZUP23 #testiscancer

[David Pook @docpook]

Laura Porter discussing tumour microenvironment manipulation with carboplatin to improve uptake of Lewis Y targeted CAR T cells into prostate tumours. Keeping the dream of effective immunotherapy in prostate cancer alive. #ANZUP23

[ANZUP @ANZUPtrials]

#ANZUP23 ASM is happening tomorrow! This is your final opportunity to register for the premier GU cancer meeting in the region. Secure your spot now at https://t.co/2TYoH5oGQx. We look forward to seeing you at Melbourne Convention Centre.

[ANZUP @ANZUPtrials]

New to the #ANZUP23 ASM, The Perfect Pitch workshop is chaired by @_ShankarSiva and @ciaraconduit. It is designed to discuss how to pitch an idea and how to bring new concepts forward for idea development, which could potentially move on to a fully fledged clinical trial.